drugset / Trial / NCT01539330

Assessment of Target Site Pharmacokinetics of Voriconazole in Healthy Volunteers During Sequence Therapy

NCT01539330

NaSingle-groupOpen-label

Summary

The present study aims at measuring unbound voriconazole concentrations in plasma and at the relevant target site of systemic fungal infections, i.e. the interstitial space fluid of soft tissues, to assess the target site pharmacokinetics. For this purpose the microdialysis technique will be employed which is capable of measuring the unbound, microbiologically active concentration of antifungals in the interstitial space fluid of virtually all tissues. This is the first human study of this drug employing the microdialysis technique determining the target site concentrations over several days (single and multiple dosing).

Timeline

Start
2009-02
Primary completion
2013-02
Completion
2013-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Voriconazole Small molecule 200 mg Intravenous

Indications

No indication recorded.